Castration-resistant metastatic prostate cancer: Current status and treatment possibilities

Clinical and Translational Oncology

Volumn 14, Issue 3, 2012, Pages 169-176

  Carles, Joan ^a,g   Castellano, Daniel ^b   Climent, Miguel Ángel ^c   Maroto, Pablo ^d   Medina, Rafael ^e   Alcaraz, Antonio ^f  

^a Instituto de Oncología de la Vall d'Hebron   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cabazitaxel; Castration resistant prostate cancer; Hormonal therapies; Metastatic prostate cancer; Progression

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANTIANDROGEN; CABAZITAXEL; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; ERIBULIN; ESTRAMUSTINE; FOSFESTROL; GALETERONE; GEMCITABINE; GONADORELIN DERIVATIVE; HYDROCORTISONE; IXABEPILONE; KETOCONAZOLE; MEDIVATION; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SATRAPLATIN; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ASTHENIA; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FLUID RETENTION; HEMATURIA; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; NEUTROPENIA; ORCHIECTOMY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; SURVIVAL TIME; TUMOR GROWTH;

CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 84860709730     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0780-8     Document Type: Review

References (39)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146-8151 (Pubitemid 46211547)
3. Uchio EM, Aslan M, Wells CK et al (2010) Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 170:1390-1395
4. Eisenberger MA, Simon R, O'Dwyer PJ, Friedman HA (1985) A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841 (Pubitemid 15062911)
5. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109 (Pubitemid 23049638)
6. Tannock IF, de Wit R, Berry WR et al; on behalf of the TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512 (Pubitemid 39315317)
7. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520 (Pubitemid 39315318)
8. Berry DL, Moinpour CM, Jiang CS et al (2006) Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 24:2828-2835 (Pubitemid 46630582)
9. Rosenberg JE, Weinberg VK, Kelly WK et al (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110:556-563 (Pubitemid 47106144)
10. Tannock IF, Osoba D, Stockler MR et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764 (Pubitemid 26185452)
11. Scher HI, Halabi S, Tannock I et al (2008) Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
12. Van Allen EM, Ryan CJ (2009) Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol 19:315-321
13. Hotte SJ, Saad F (2001) Current management of castrate-resistant prostate cancer. Curr Oncol 17[Suppl 2]:S72-79
14. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572 (Pubitemid 23228264)
15. Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALBG 9583). J Clin Oncol 22:1025-1033 (Pubitemid 41095034)
16. Sartor AO, Tangen CM, Hussain MH et al (2008) Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112:2393-2400
17. Suzuki H, Okihara K, Miyake H et al (2008) Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180:921-927
18. Hussain M, Wolf M, Marshall E et al (1994) Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormonerefractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12:1868-1875
19. Oh WK, Kanthoff PW, Weinberg V et al (2004) Prospective, multicentre, randomized phase II trial of the herbal supplement PC-SPES and diethylbestrol in patients with androgen-independent prostate cancer. Clin Oncol 22:3705-3712 (Pubitemid 41095210)
20. Orlando M, Chacon A, Salum G, Chacon DR (2000) Low dose continuous oral fosfestrol is highly active in hormone refractory prostate cancer. Ann Oncol 11:177-181 (Pubitemid 30148731)
21. Kantoff PW, Halabi S, Conaway M et al (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B9182 study. J Clin Oncol 17:2506-2513 (Pubitemid 29368252)
22. Ryan CJ, Eisenberger M (2005) Chemotherapy for hormone-refractory prostate cancer: now it's a question of when? J Clin Oncol 23:8242-8246 (Pubitemid 46211561)
23. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate level of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148
24. Scher HI, Warren M, Heller G (2007) The association between measures of progression and survival in castrate metastatic prostate cancer. Clin Cancer Res 13:1488-1492 (Pubitemid 46450439)
25. Armstrong AJ, Garret-Mayer E, de Wit R et al (2010) Prediction of survival following ? rst line chemotherapy in men with castration resistant metastatic prostate cancer. Clin Cancer Res 16: 203-211
26. Berthold DR, Pond GR, de Wit R et al (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749-1753
27. Fontana A, Galli L, Fioravanti A et al (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 15:4954-4962
28. Sternberg CN (2007) Satraplatin demonstrates a signi? cant clinical bene? t in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol
29. Attard G, Greystoke A, Kaye S, de Bono J (2006) Update on tubulin-binding agents. Pathol Biol (Paris) 54:72-84
30. Bissery M-C (2001) Preclinical evaluation of new taxoids. Curr Pharm Des 7:1251-1257 (Pubitemid 32798807)
31. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147-1154
32. FDA Center for Drug Evaluation and Research. Approval Package for: Jevtana. June 17, 2010. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2010/201023s000Approv. pdf. Accessed February 2, 2011
33. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
34. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-1446
35. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
36. Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247-4254
37. Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 28:1099-1105
38. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
39. Sonpavde G, Sternberg CN (2011) Contemporary management of metastatic castration-resistant prostate cancer. Curr Opin Urol 21:241-247